Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody

Abstract

Invasion of erythrocytes by Plasmodial merozoites is a composite process involving the interplay of several proteins. Among them, the Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA) is a crucial component of a ternary complex, including Reticulocyte binding-like Homologous protein 5 (PfRH5) and the RH5-interacting protein (PfRipr), essential for erythrocyte invasion. Here we present the crystal structure of PfCyRPA and of its complex with the antigen-binding fragment of a parasite growth inhibitory antibody. While PfCyRPA adopts a 6-bladed β-propeller structure with similarity to the classic sialidase fold, it possesses no sialidase activity, indicating that it fulfills a non-enzymatic function. Characterization of the epitope recognized by protective antibodies will facilitate design of peptidomimetics that focus vaccine responses on protective epitopes. Both in vitro and in vivo anti-PfCyRPA and anti-PfRH5 antibodies showed more potent parasite growth inhibitory activity in combination than on their own, supporting a combined delivery of PfCyRPA and PfRH5 in vaccines.

Data availability

The following data sets were generated
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZI).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZL).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZJ).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of PfCyRPA
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZN).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of PfCyRPA
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZO).
The following previously published data sets were used

Article and author information

Author details

  1. Paola Favuzza

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1394-927X
  2. Elena Guffart

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  3. Marco Tamborrini

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Bianca Scherer

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  5. Anita M Dreyer

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  6. Arne C Rufer

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  7. Johannes Erny

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  8. Joerg Hoernschemeyer

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  9. Ralf Thoma

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  10. Georg Schmid

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  11. Bernard Gsell

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  12. Araceli Lamelas

    Red de Estudios Moleculares Avanzados, Instituto de Ecología A.C., Xalapa, Mexico
    Competing interests
    The authors declare that no competing interests exist.
  13. Joerg Benz

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  14. Catherine Joseph

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  15. Hugues Matile

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  16. Gerd Pluschke

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    For correspondence
    Gerd.Pluschke@unibas.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1957-2925
  17. Markus G Rudolph

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    For correspondence
    markus.rudolph@roche.com
    Competing interests
    The authors declare that no competing interests exist.

Funding

Uniscientia Stiftung

  • Gerd Pluschke

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures involving living animals were performed in strict accordance with the Rules and Regulations for the Protection of Animal Rights (Tierschutzverordnung) of the Swiss Federal Food Safety and Veterinary Office. The protocol was granted ethical approval by the Veterinary Office of the county of Basel-Stadt, Switzerland (Permit Numbers: 2375 and 2303).

Copyright

© 2017, Favuzza et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,117
    views
  • 629
    downloads
  • 56
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Paola Favuzza
  2. Elena Guffart
  3. Marco Tamborrini
  4. Bianca Scherer
  5. Anita M Dreyer
  6. Arne C Rufer
  7. Johannes Erny
  8. Joerg Hoernschemeyer
  9. Ralf Thoma
  10. Georg Schmid
  11. Bernard Gsell
  12. Araceli Lamelas
  13. Joerg Benz
  14. Catherine Joseph
  15. Hugues Matile
  16. Gerd Pluschke
  17. Markus G Rudolph
(2017)
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody
eLife 6:e20383.
https://doi.org/10.7554/eLife.20383

Share this article

https://doi.org/10.7554/eLife.20383

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Cristina Paissoni, Sarita Puri ... Carlo Camilloni
    Research Article

    Both immunoglobulin light-chain (LC) amyloidosis (AL) and multiple myeloma (MM) share the overproduction of a clonal LC. However, while LCs in MM remain soluble in circulation, AL LCs misfold into toxic-soluble species and amyloid fibrils that accumulate in organs, leading to distinct clinical manifestations. The significant sequence variability of LCs has hindered the understanding of the mechanisms driving LC aggregation. Nevertheless, emerging biochemical properties, including dimer stability, conformational dynamics, and proteolysis susceptibility, distinguish AL LCs from those in MM under native conditions. This study aimed to identify a2 conformational fingerprint distinguishing AL from MM LCs. Using small-angle X-ray scattering (SAXS) under native conditions, we analyzed four AL and two MM LCs. We observed that AL LCs exhibited a slightly larger radius of gyration and greater deviations from X-ray crystallography-determined or predicted structures, reflecting enhanced conformational dynamics. SAXS data, integrated with molecular dynamics simulations, revealed a conformational ensemble where LCs adopt multiple states, with variable and constant domains either bent or straight. AL LCs displayed a distinct, low-populated, straight conformation (termed H state), which maximized solvent accessibility at the interface between constant and variable domains. Hydrogen-deuterium exchange mass spectrometry experimentally validated this H state. These findings reconcile diverse experimental observations and provide a precise structural target for future drug design efforts.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Yi-Hsuan Lin, Tae Hun Kim ... Hue Sun Chan
    Research Article

    Liquid-liquid phase separation (LLPS) involving intrinsically disordered protein regions (IDRs) is a major physical mechanism for biological membraneless compartmentalization. The multifaceted electrostatic effects in these biomolecular condensates are exemplified here by experimental and theoretical investigations of the different salt- and ATP-dependent LLPSs of an IDR of messenger RNA-regulating protein Caprin1 and its phosphorylated variant pY-Caprin1, exhibiting, for example, reentrant behaviors in some instances but not others. Experimental data are rationalized by physical modeling using analytical theory, molecular dynamics, and polymer field-theoretic simulations, indicating that interchain ion bridges enhance LLPS of polyelectrolytes such as Caprin1 and the high valency of ATP-magnesium is a significant factor for its colocalization with the condensed phases, as similar trends are observed for other IDRs. The electrostatic nature of these features complements ATP’s involvement in π-related interactions and as an amphiphilic hydrotrope, underscoring a general role of biomolecular condensates in modulating ion concentrations and its functional ramifications.